We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000301:SZSEJiangsu Eastern Shenghong Co.,Ltd. Analysis

Data as of 2026-06-14 - not real-time

CN¥11.88

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Jiangsu Eastern Shenghong is trading at CNY 11.88, just above the calculated support of CNY 11.21 and well below the resistance of CNY 12.94, indicating limited upside in the near term. The technical picture is mixed: RSI sits at 45.5 (neutral), the MACD histogram is negative and the signal line is bearish, while volume is on a decreasing trend, suggesting weakening buying pressure. Despite a market‑wide “Extreme Greed” sentiment (fear‑greed index 89.86), the stock’s 30‑day volatility is high at 26.5% and its beta is only 0.11, implying that price swings are driven more by company‑specific factors than broad market moves.
Fundamentally, the company appears overvalued with a trailing P/E of 66 versus a forward P/E of 19.5, a price‑to‑book of 2.17 and a price‑to‑sales of 4.83. The balance sheet is strained – debt‑to‑equity exceeds 370, while cash flow metrics are zero and margins hover around 8‑15%. No dividend is paid, and ROE/ROA are effectively nil. Combined with modest revenue growth (5.7%) and a cyclical chemicals sector, the outlook is challenged, prompting a cautious stance.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD and decreasing volume signal weakening momentum
  • Current price barely above support with limited upside
  • Trailing P/E of 66 indicates significant overvaluation

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt‑to‑equity ratio constrains financial flexibility
  • Modest revenue growth and low operating margins
  • Sector cyclicality may create temporary price stabilization

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Unsustainable capital structure with negligible cash flow
  • Zero dividend yield and stagnant ROE/ROA
  • Potential regulatory tightening on chemical production in China

Key Metrics & Analysis

Financial Health

Revenue Growth5.70%
Profit Margin8.33%
P/E Ratio66.0
Debt/Equity370.27
P/B Ratio2.2

Technical Analysis

TrendNeutral
RSI45.5
SupportCN¥11.21
ResistanceCN¥12.94
MA 20CN¥12.11
MA 50CN¥12.17
MA 200CN¥10.90
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Target PriceCN¥13.40
Upside/Downside12.79%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.11
Volatility26.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.